ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: SA-PO698

Comparison of Mesenchymal Stem Cells (MSCs) and Extracellular Vesicles (EVs) in the Treatment of Experimental Peritoneal Fibrosis

Session Information

  • Peritoneal Dialysis - II
    November 04, 2017 | Location: Hall H, Morial Convention Center
    Abstract Time: 10:00 AM - 10:00 AM

Category: Dialysis

  • 608 Peritoneal Dialysis

Authors

  • Gouveia, Priscila Q, University of São Paulo, São Paulo, Brazil
  • Silva, Cleonice, University of São Paulo, São Paulo, Brazil
  • Noronha, Irene L., University of São Paulo, São Paulo, Brazil
Background

Long-term peritoneal dialysis is associated with the development of structural and functional changes in the peritoneal membrane, leading to fibrosis and ultrafiltration failure. Infusion of MSCs represents a potential strategy to treat fibrotic processes, due to paracrine effects. EVs released by MSCs are responsible for cell-cell interactions and possibly for the therapeutic effects of MSCs on tissue regeneration. Our aim was to compare the effects of MSCs with EV in an experimental model of peritoneal fibrosis (PF).

Methods

PF was induced in male Wistar rats by intraperitoneal (IP) injections of 0.1% chlorhexidine gluconate (CG), on alternate days for 30 days. MSCs obtained from adipose tissue were isolated and characterized by flow cytometry and in vitro differentiation. EVs obtained from MSCs supernatants were isolated by differential ultracentrifugation and characterized by Bradford assay, Zetasizer Nano and scanning electron microscopy. MSCs or EVs were administrated IP on days 3 and 10 after PF induction. The study groups consisted of: Control (n=6), normal rats receiving only vehicle (saline); PF (n=9), rats receiving CG injections to develop PF; PF+MSC (n=7), PF rats treated with 2x106 MSCs and PF+EV (n=7), PF rats treated with 30µg EVs.

Results

Administration of MSCs or EVs prevented peritoneal thickening and ameliorated ultrafiltration. Both treatments significantly decreased the expression of genes associated with fibrosis (TGF-β,FSP-1 and SMAD3). In addition, both treatments reduced the inflammatory infiltrate and the expression of TNF-α and VEGF.

Conclusion

We conclude that MSCs and EVs are equally efficient in blocking the PF process in this experimental model of PF.

 ControlPFPF+MSCPF+VE
Peritoneal Thickness(μm)26±064±14*23±2#26±6#
Ultrafiltration(mL)13±13±1*5±1*#6±1*#§
TGF-β(mRNA)1±112±1*3±1#1±0#
FSP-1(mRNA)1±118±1*1±0#1±0#
Smad-3(mRNA)1±08±1*1±0#1±1#
Macrophages(cells/mm2)106±35404±122*263±49*#147±17#
T-cells(cell/mm2)4±187±31*7±3#11±4#
VEGF(mRNA)1±121±2*4±3#2±1#
TNF-α(mRNA)1±114±1*1±1#1±1#

*p<0.05vsControl;#p<0.05vsPF;§<0.05vsFP+MSC

Funding

  • Government Support - Non-U.S.